New Data to be Presented at ASTRO 2021 Further Validate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier - Seite 2
Abstract #:
94 (oral presentation)
Presenter:
Alan Dal Pra, M.D., University of Miami - Sylvester Cancer Center
Location:
McCormick Place West, Room W181 a/b/c
About Veracyte
Veracyte (Nasdaq: VCYT) is a global diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment
decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of diagnostic tests leverages advances in genomic science and technology, enabling patients to
avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company’s tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer, colon
cancer, and idiopathic pulmonary fibrosis are available to patients and its renal cancer and lymphoma subtyping tests are in development, the latter as a companion diagnostic. With Veracyte’s
exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its genomic tests to patients worldwide. Veracyte is based in South San Francisco,
California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).
Lesen Sie auch
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, our statements related to our plans,
objectives, expectations (financial and otherwise) or intentions with respect to the Decipher Prostate genomic classifier. Forward-looking statements can be identified by words such as:
"anticipate," "intend," "plan," "expect," "believe," "should," “suggest,” "may," "will," “prospective” and similar references to future periods. Actual results may differ materially from those
projected or suggested in any forward-looking statements. Examples of forward-looking statements include, among others, statements regarding Veracyte’s belief that its Decipher Prostate test can
positively influence therapeutic decision-making in prostate cancer. Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual
Report on Form 10-K filed with the SEC on February 22, 2021 and our subsequent quarterly reports on Form 10-Q. A copy of these documents can be found at the Investors section of our website at
www.veracyte.com. These forward-looking statements speak only as of the date hereof and, except as required by law, Veracyte specifically disclaims any obligation
to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.